In anticipation of its presentation at the J.P. Morgan Global Healthcare Conference, obesity drugmaker VIVUS released its presentation in an SEC filing. Investors were particularly impressed with the improved prescription data for Qsymia, and shares jumped around 8% today on this news. In the following video, health care analyst Max Macaluso discusses this news, reasons for why Qsymia prescriptions are gaining momentum, and what this means for Arena Pharmaceuticals -- VIVUS' main competitor in the obesity drug market.
Shares of VIVUS have been under pressure since Qsymia's initial sales numbers were released in November, but the stock is still up 45% in the last 12 months. While the jury's out on this biotech's long-term success, some investors were able to make great returns by recognizing the game-changing potential of its recently approved obesity drug. That is the same mind-set that Motley Fool co-founder David Gardner's often uses to pick stocks that frequently trounce the market. He's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
The article Will VIVUS Prove Doubters Wrong? originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.